株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

糖尿病性神経障害:パイプライン分析

Diabetic Neuropathy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192558
出版日 ページ情報 英文 117 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
糖尿病性神経障害:パイプライン分析 Diabetic Neuropathy - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 117 Pages
概要

糖尿病性神経障害は、糖尿病でよく見られる合併症で、痛みなどを感じることができる神経の損傷です。うずき、しびれ、灼熱感、痛みなどの症状が見られます。素因として、肥満、高血圧、高脂質・高血糖、喫煙などが挙げられます。投薬治療や食習慣の改善で、管理することが可能です。

当レポートでは、糖尿病性神経障害に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

糖尿病性神経障害の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Achelios Therapeutics, Inc.
  • Araim Pharmaceuticals, Inc.
  • Celgene Corporation
  • Commence Bio, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Glucox Biotech AB
  • Kineta, Inc.
  • Lpath, Inc.
  • Neuralstem, Inc.
  • NovaLead Pharma Pvt. Ltd.
  • Omeros Corporation
  • PhiloGene, Inc.
  • Reata Pharmaceuticals, Inc.
  • Relief Therapeutics S.A.
  • Sucampo Pharmaceuticals, Inc.
  • 大日本住友製薬
  • ViroMed Co., Ltd.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8653IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Diabetic Neuropathy.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Neuropathy Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Neuropathy - Overview
    • Pipeline Products for Diabetic Neuropathy - Comparative Analysis
  • Diabetic Neuropathy - Therapeutics under Development by Companies
  • Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Neuropathy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Diabetic Neuropathy - Products under Development by Companies
  • Diabetic Neuropathy - Products under Investigation by Universities/Institutes
  • Diabetic Neuropathy - Companies Involved in Therapeutics Development
    • Achelios Therapeutics, Inc.
    • Araim Pharmaceuticals, Inc.
    • Celgene Corporation
    • Commence Bio, Inc.
    • Glucox Biotech AB
    • KPI Therapeutics, Inc.
    • Lpath, Inc.
    • Medifron DBT Co., Ltd.
    • Neuralstem, Inc.
    • NovaLead Pharma Pvt. Ltd.
    • Novartis AG
    • Omeros Corporation
    • PhiloGene, Inc.
    • Reata Pharmaceuticals, Inc.
    • Relief Therapeutics S.A.
    • Sucampo Pharmaceuticals, Inc.
    • ViroMed Co Ltd
  • Diabetic Neuropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • atexakin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benfotiamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNV-222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cibinetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EMA-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lpathomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDR-652 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLP-198 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDA-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pirenzepine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RTA-901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RTU-1096 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Diabetic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XK-568b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Diabetic Neuropathy - Dormant Projects
  • Diabetic Neuropathy - Discontinued Products
  • Diabetic Neuropathy - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy
      • Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
      • Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
      • Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab
      • Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting
      • Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial
      • Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Neuropathy, H2 2016
  • Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diabetic Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Celgene Corporation, H2 2016
  • Diabetic Neuropathy - Pipeline by Commence Bio, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H2 2016
  • Diabetic Neuropathy - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Lpath, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Medifron DBT Co., Ltd., H2 2016
  • Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016
  • Diabetic Neuropathy - Pipeline by Novartis AG, H2 2016
  • Diabetic Neuropathy - Pipeline by Omeros Corporation, H2 2016
  • Diabetic Neuropathy - Pipeline by PhiloGene, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H2 2016
  • Diabetic Neuropathy - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diabetic Neuropathy - Dormant Projects, H2 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..1), H2 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..2), H2 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..3), H2 2016
  • Diabetic Neuropathy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Diabetic Neuropathy, H2 2016
  • Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top